课题基金 / 基金详情

Coordination Funds

Coordination Funds
协调基金
批准号:
426581255
负责人:
Professor Dr. Christoph Schramm
金额:
$0.0万
依托单位国家:
德国
项目类别:
Clinical Research Units
财政年份:
2019
资助国家:
德国
项目状态:
已结题
起止时间:
2018-12-31 至 2023-12-31
关键词:

项目摘要

项目成果

Professor Dr. Christoph Schramm的其他基金

相似基金

相关文献

中文摘要
翻译
原发性硬化性胆管炎(PSC)是一种相对罕见的慢性进行性胆管疾病,可导致肝硬变和胆管癌。到目前为止,还没有有效的治疗方法来改变疾病的进展过程。肝硬变和肝胆恶性肿瘤的高风险限制了患者的生存,但与健康相关的生活质量经常受到PSC相关并发症的影响,如骨质疏松。PSC的特点是肝内外胆管的炎症和纤维化,并与炎症性肠道疾病密切相关,最常见的是PSC相关性全结肠炎。这些疾病特征强调了粘膜表面在疾病发病机制中的重要性。近年来,微生物群对维持和打破粘膜免疫稳态起着关键作用。在CRU306中,我们假设微生物组及其相关的免疫和代谢变化决定了疾病的发病机制和病程。在以前的工作中,我们可以证明PSC与肠道微生物区系的变化有关,这在地理区域内得到了验证,最近还与胆道微生物区系的变化有关。我们已经证明PSC与血液和肝脏中免疫细胞群的改变有关,PSC患者的T细胞在热灭活细菌刺激后显示出更多的促炎细胞因子的产生。CRU汇集了肝病学、免疫学、微生物组研究和生物信息学方面的一些临床和基础科学专家。在下一个资助阶段,我们将重点研究观察到的与PSC相关的微生物区系、免疫学和代谢模式的变化在人类和各自的小鼠模型中的疾病发病机制、表型和疾病进程方面的功能意义。
英文摘要
Primary Sclerosing Cholangitis (PSC) is a relatively rare, chronic progressive disease of bile ducts which leads to liver cirrhosis and cholangiocarcinoma. To date there is no effective therapy to alter the progressive course of disease. Patient survival is limited by the high risk of cirrhosis as well as hepatobiliary malignancy, but in addition health related quality of life is often impaired by PSC-associated complications such as osteoporosis.PSC is characterized by inflammation and fibrosis of intra- and/or extrahepatic bile ducts and by its strong association with inflammatory bowel disease, most often PSC-asssociated pancolitis. These disease features underline the importance of the mucosal surface for disease pathogenesis. In recent years it has become clear that the microbiome is critical for the maintenance and breach of mucosal immune homeostasis. Within the CRU306 we hypothesize that the microbiome and its associated immunological and metabolic changes determine disease pathogenesis and course. In previous work we could show that PSC is associated with changes in intestinal microbiota composition, which were validated across geographical regions, and recently also with changes in the biliary microbiota. We have shown that PSC is associated with altered immune cell populations in blood and liver and that T cells from patients with PSC showed increased pro-inflammatory cytokine production after stimulation with heat-inactivated bacteria. The CRU brings together a number of clinical and basic science experts in hepatology, immunology, microbiome research and bioinformatics. In the next funding period we will focus on the functional meaning of the observed changes in PSC-associated microbiota, immunological and metabolic patterns with regard to disease pathogenesis, phenotype and disease course in humans and respective mouse models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular pathogenesis and signaling pathways: identification of therapeutic targets in primary sclerosing cholangitis (PSC)
  • 批准号:
    417889840
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    Professor Dr. Christoph Schramm
  • 依托单位:
Regulatorische T-Zellen in der Therapie entzündlicher Lebererkrankungen
  • 批准号:
    35346795
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2007
  • 负责人:
    Professor Dr. Christoph Schramm
  • 依托单位:
Mechanismen der Asthmaresistenz durch regulatorische T-Zellen und TGFß1
  • 批准号:
    5420981
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2003
  • 负责人:
    Professor Dr. Christoph Schramm
  • 依托单位:
The role of androgens in autoimmune liver diseases
  • 批准号:
    453861134
  • 项目类别:
    Research Units
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Professor Dr. Christoph Schramm
  • 依托单位:
海外基金